Merkel cell carcinoma presenting as right leg edema in a multiple myeloma patient

Noell, Claire; Rose, Elizabeth; Nesbitt, Lee T.

doi:10.1016/j.jaad.2014.01.882

Cited by 5 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement with the retrospective studies/literature reviews, findings from the small-sized case reports may suggest that the proportion of patients achieving a PR was higher among patients receiving chemotherapy in the first-line setting (24% or 4 of 17 patients) compared with the second-line setting (20% or 1 of 5 patients) [ 64 , 67 , 68 ]. None of the patients treated in the third- or fourth-line settings achieved a CR [ 59 , 63 ]. The proportion of patients achieving a CR was slightly higher among those receiving platinum-containing regimes compared with non-platinum-containing regimens (21 vs 17%, respectively).…”

Section: Resultsmentioning

confidence: 99%

Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma

et al. 2017

View full text Add to dashboard Cite

Aim:Merkel cell carcinoma (MCC) is a rare neuroendocrine, cutaneous malignancy with poor prognosis once metastasized. The aim of this study was to conduct a systematic literature review to assess clinical outcomes associated with chemotherapy regimens in metastatic MCC.>Materials & methods:Embase®, MEDLINE®, MEDLINE®-In-Process and CENTRAL were searched for studies published in January 2016.Results & conclusion:Overall, the literature on chemotherapy in patients with metastatic MCC is sparse, with most studies being case series/reports. Across all studies, response rates ranged from 20 to 61%, with higher response rates in first-line setting (53–61%) versus second-line setting (23–45%). Among responders, duration of response was short (≤8 months) in both first- and second-line settings. There is a need for novel agents that can induce durable responses in metastatic MCC.

show abstract

Section: Resultsmentioning

confidence: 99%

Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Only 13 cases [5][6][7][8][9][10][11][12][13][14][15][16][17] met the condition of having a retroperitoneal Merkel cell involvement without primary skin lesion, they are summarized in Table 1. Most of the cases had retroperitoneal nodal affection (7 cases) or pancreatic involvement (2 cases), with only 4 plus our case with a real retroperitoneal mass of unknown origin that could be classified as the main tumor [5][6][7][8].…”

Section: Literature Review Resultsmentioning

confidence: 99%

Retroperitoneal Merkel Cell Carcinoma without Skin Involvement: Literature Review and One Case Experience

Sota¹,

Vila²,

Giménez³

et al. 2017

Ann Clin Lab Res

View full text Add to dashboard Cite

Merkel cell carcinoma (MCC) is an uncommon neuroendocrine tumor that represents a small percentage of skin malignancies, with an aggressive behavior and survival rate at 5 years of 20% to 80%. Among the risk factors, we find Ultraviolet radiation, polyomavirus, other malignancies and immunosuppression.Most of the MCC are diagnosed over 59 years old, being more frequent in men. According to the literature, only 2% to 5% had no skin involvement. Among regions involved, head and neck are the most frequent, followed by limbs and lymph nodes.We described a case of MCC without skin involvement, atypically located in retroperitoneum and given the rarity of both circumstances, we also conducted a review of the reported cases of retroperitoneal MCC without skin tumor.Among retroperitoneal MCC without primary skin involvement, we found 13 reported cases, the average age of these patients was 66 years old, being female only one case. They were all diagnosed by computerized tomography (CT) or Positron emission tomographycomputed tomography (PET-CT). The size of the main mass was variable (15 cm to 3 cm) and selected treatments were chemotherapy, surgery and radiation therapy. Survival rate is unknown in most of them.

show abstract

“…All reports linking lenalidomide to peripheral edema have largely been suspected to be linked to tumor lysis syndrome or venous thromboembolic events (10). One case report describes a 61-year-old man with multiple myeloma who was treated with this chemotherapy regimen who presented with persistent right lower extremity edema and pain, had a negative duplex study, and was ultimately found to have Merkel Cell carcinoma (11). While this case could represent a similar presentation of lymphedema related to lenalidomide or bortezomib, the story is complicated by the known relationship between aggressive, bulky carcinoma and lymphedema (12).…”

Section: Discussionmentioning

confidence: 99%

Iatrogenic Systemic Lymphedema Following Multiple Myeloma Treatment

Radu¹,

Wilson²,

Bagwell³

et al. 2022

Lymphology

View full text Add to dashboard Cite

Lymphedema is a debilitating disease characterized by abnormal lymphatic drainage, either due to primary maldevelopment of the lymphatic system or to secondary injury. The clinical features of primary and secondary lymphedema differ, with primary lymphedema more often involving progressive bilateral lower extremity disease as compared to secondary lymphedema characteristically having more localized symptoms related to the origin of injury. This case presentation describes a patient who presented with bilateral lower extremity swelling, left greater than the right, with im- aging results to support the diagnosis of lymphedema. During the time he was followed in our clinic, our team witnessed rapid progression of his lymphedema despite compliance with conservative management. We believe that the primary mechanism of systemic damage to our patient's lymphatic system is the lenalidomide and bortezomib therapy prescribed to treat multiple myeloma. This review explores the relationship between lenalidomide, bortezomib, and lymphedema in efforts of understanding this unique pathology of iatrogenic lymphedema mimicking primary nature.

show abstract

Merkel cell carcinoma presenting as right leg edema in a multiple myeloma patient

Cited by 5 publications

References 3 publications

Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma

Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma

Retroperitoneal Merkel Cell Carcinoma without Skin Involvement: Literature Review and One Case Experience

Iatrogenic Systemic Lymphedema Following Multiple Myeloma Treatment

Contact Info

Product

Resources

About